Therapeutic monoclonal antibodies

Taketo Yamada

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalKeio Journal of Medicine
Volume60
Issue number2
Publication statusPublished - 2011 Jun

Fingerprint

Monoclonal Antibodies
Magic
Drug Industry
Therapeutic Uses
Biotechnology
Cell Biology
Immunoglobulins
Molecular Biology
Therapeutics
History
Medicine
Antibodies
Serum

Keywords

  • Immunoglobulin
  • Molecular target therapy
  • Monoclonal antibody

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic monoclonal antibodies. / Yamada, Taketo.

In: Keio Journal of Medicine, Vol. 60, No. 2, 06.2011, p. 37-46.

Research output: Contribution to journalArticle

Yamada, T 2011, 'Therapeutic monoclonal antibodies', Keio Journal of Medicine, vol. 60, no. 2, pp. 37-46.
Yamada, Taketo. / Therapeutic monoclonal antibodies. In: Keio Journal of Medicine. 2011 ; Vol. 60, No. 2. pp. 37-46.
@article{36a512cb1d3343a9a294590c09e8ad2d,
title = "Therapeutic monoclonal antibodies",
abstract = "Over a hundred years has passed since the discovery of the {"}magic bullet{"} serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.",
keywords = "Immunoglobulin, Molecular target therapy, Monoclonal antibody",
author = "Taketo Yamada",
year = "2011",
month = "6",
language = "English",
volume = "60",
pages = "37--46",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",

}

TY - JOUR

T1 - Therapeutic monoclonal antibodies

AU - Yamada, Taketo

PY - 2011/6

Y1 - 2011/6

N2 - Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.

AB - Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.

KW - Immunoglobulin

KW - Molecular target therapy

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=80051941878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051941878&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 37

EP - 46

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 2

ER -